{
  "docId": "019de074-ac90-73cc-861b-68f2ee02d519",
  "docSlug": "5e6566e4cd37b5a4c67661e229e01a81",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 41 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 41,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a two-column layout to contrast near-term R&D milestones with long-term corporate strategy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ac90-73cc-861b-68f2ee02d519/29",
  "deckHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519",
  "deckJsonHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519.json",
  "deckAnchorHref": "/decks/019de074-ac90-73cc-861b-68f2ee02d519#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "1. Indicates Company ambition to achieve Total Revenue low double-digit CAGR through 2025...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73ff861e-511e-465c-952c-fadb50943814",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Pipeline advances in 2023 with 18 Phase III read-outs anticipated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84f88148-f044-4833-b4a7-e78ee79ef599",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.25
      },
      "kind": "list",
      "text": "Sustainable, long-term growth through commercial execution, R&D impact and ESG",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87131096-3cb7-40c0-8e7f-db9ee76026d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Accelerating pipeline momentum, disciplined investment fuels industry-leading growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "741eeef0-c3fb-4bcb-b4ef-48db896ba91c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca – Q1 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62585c03-b9a6-4246-87ad-3c619440387c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "9bcaf4a3-2933-49e1-9d81-1dd3e6f1c61c",
      "evidence": "title/action-title: Accelerating pipeline momentum, disciplined investment fuels industry-leading growth",
      "confidence": 0.8
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b12e3a2b-247e-4bfd-a007-c0e8a71c474c",
      "evidence": "list/bullet: Sustainable, long-term growth through commercial execution, R&D impact and ESG",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 27,
      "beatId": "d4748166-ff02-4485-af4c-160000f223c2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The closing remarks and key takeaways provide a visualization of the company's future prospects",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}